Reimbursement for medicinal cannabis

It is possible to get a special reimbursement when buying cannabis products that are covered by the pilot programme.

Total cost (12 mth) Reimbursement Co-payment
DKK 0 – 20,000 50% Up to DKK 10,000
More than DKK 20,000 0% Total product price
Reimbursement for the terminally ill 100% No co-payment

You can find further information at Lægemiddelstyrelsens hjemmeside or by calling the clinic at: +45 3132 1434.

Single reimbursement 

Single reimbursement is an option if you have followed a certain treatment guide and have received treatment with approved pharmaceutical products. The doctor can apply for reimbursement on your behalf, and the processing time for the application is approx. 14 days.

Reimbursement from Sygeforsikringen “danmark”

If you are a member of Sygeforsikringen “danmark” (private health insurance), you may receive additional reimbursement, depending on your membership group. This applies to all medicine, and therefore also medicinal cannabis and cannabis-based medicine. When you pick up your medicine at the pharmacy, you simply specify which health insurance group you belong to, and you automatically receive the reimbursement. Please refer to for more information.

Reimbursement for the terminally ill

​As doctors, we can apply for reimbursement for the terminally ill on your behalf. It is possible to apply for additional reimbursement for patients who are terminally ill. If the reimbursement application is approved, all medicine will be free of charge.

About reimbursement for medicinal cannabis and cannabis-based medicine

The above are the only three options available for reimbursement for consultations, medicinal cannabis and cannabis-based medicine.

The Danish Medicines Agency is able to grant reimbursement to patients with conditions where cannabis-based medicine and medicinal cannabis are likely to have an effect. Medicinal cannabis is not a marketed pharmaceutical (like a broad range of other pharmaceuticals), and we therefore have to follow the national guidelines for treatment of neuropathic pain, despite the fact that all other treatments with approved pharmaceuticals (Tramadol, TCA, Gabapentin, Lyrica, Duloxetine, Venlafaxine) have been tested without sufficient effects.

The applications are processed individually by the Danish Medicines Agency. It is the responsibility of the patients to check the approved reimbursement – and in due time inform the clinic when it is time to reapply for the relevant reimbursement.